Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center, discusses the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice.
This on-demand webinar was originally broadcast on June 24, 2026.
What will this webinar empower you to do?
• Recognize the clinical significance of distinguishing HER2 IHC 0 with faint, incomplete membrane staining
• Apply best practices for accurate HER2 IHC assessment
• Implement standardized reporting that clearly communicates semiquantitative (discrete)
HER2 IHC scores and level of membrane staining
Moderated by: Bob McGonnagle, Publisher, CAP TODAY.
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.